Arcellx (ACLX) Files IPO Registration Statement

Arcellx (NASDAQ: ACLX) has filed for a proposed IPO.

The company describes itself as: "We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the D-Domain, was engineered to overcome the limitations of traditional Chimeric Antigen Receptor T cells (CAR-Ts). Existing cell therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these limitations by engineering a new class of D-Domain powered autologous and allogeneic CAR-Ts, including classical single infusion CAR-Ts called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases."

BofA Securities, SVB Leerink, Barclays and William Blair will serve as underwriters.

You May Also Be Interested In

• Quantinuum (QNT) opens at $68, 13% above IPO pricing
• Parabilis Medicines (PBLS) files for 25M share IPO at $17-$19/sh
• Keystone Acquisition closes $287.5 million IPO with overallotment